Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 6/20 | 0.65 |
| ▸ | CDK2 | P24941 | 6/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | CDK4 | P11802 | 1/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.65 |
| ▸ | CCND1 | P24385 | 1/20 | 0.65 |
| ▸ | CDK7 | P50613 | 1/20 | 0.65 |
| ▸ | CDK9 | P50750 | 1/20 | 0.65 |
| ▸ | CCNH | P51946 | 1/20 | 0.65 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835404 | 0.85 | CCNE1 (0.75) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL6191790 | 0.85 | CDK2 (0.62) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL21533571 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2A | |
| SCHEMBL21533498 | 0.83 | CCNE1 (0.65) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL5835423 | 0.82 | CDK2 (0.56) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL5836598 | 0.81 | CCNE1 (0.77) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL5835952 | 0.81 | CCNE1 (0.61) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL5837242 | 0.80 | CDK2 (0.56) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL6173277 | 0.80 | CCNE1 (0.66) | CCNE1CDK2CDK5CCNT1ALDH1A1 | |
| SCHEMBL5836102 | 0.79 | CDK2 (1.00) | CCNE1CDK2CDK5CCNT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037929-B1 | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2006-05-02 | — | — | US | claimed |
| EP-1124810-B9 | 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-12-28 | — | — | EP | claimed |
| EP-1124810-B1 | 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-05-04 | — | — | EP | claimed |
| CN-1325389-A | 2-aminothiazole derivatives, process for preparing the same and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | claimed |
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2019-10-31 | — | — | US | disclosed |
| US-7037929-B1 | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2006-05-02 | — | — | US | disclosed |
| EP-1124810-B9 | 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-12-28 | — | — | EP | disclosed |
| EP-1124810-B1 | 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| CN-1325389-A | 2-aminothiazole derivatives, process for preparing the same and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | NFATC1, EP300, CD69 | CCNE1 785/4885CDK2 120/4885CDK5 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.